Biogen IncNasdaq: BIIB
Health Care · Biotechnology
$196.51
-1.09%
Vol: 745K
Research Digest
Friday, June 19, 2026
Biogen agrees to acquire immunology biotech RayThera for up to $1 billion to expand its anti-inflammatory pipeline, with the lead asset entering Phase 1 in Q3 2026.
Biogen announced on June 18, 2026 that it will acquire San Diego-based private biotech RayThera Inc. for up to $1 billion, consisting of an upfront payment plus clinical and regulatory milestone payments. RayThera's portfolio adds multiple anti-inflammatory assets targeting immune-mediated conditions, with the lead candidate expected to enter Phase 1 clinical trials in early Q3 2026. BIIB stock dipped modestly in after-hours trading following the announcement, trading around $198 per share. Needham reiterated its Buy rating on Biogen after the deal was announced. Wall Street's consensus stands at Moderate Buy with an average price target of $223, implying roughly 12% upside; the acquisition diversifies Biogen beyond neurology but increases pipeline risk ahead of Phase 1 data readouts.
Previous Market Intelligence
13 daysJun 18Biogen agreed to acquire San Diego-based RayThera in a deal worth up to $1 billion to strengthen its immunology pipeline.Positive▶
On June 17, 2026, Biogen announced an agreement to acquire RayThera Inc., a San Diego biotech developing small-molecule anti-inflammatory drugs for immune-mediated diseases, in a transaction valued at up to $1 billion. This is Biogen's second major acquisition of the year, following its roughly $5.6 billion purchase of Apellis Pharmaceuticals in March 2026. The deal extends Biogen's strategy of bolstering its pipeline through M&A as it faces ongoing revenue declines in legacy franchises. It builds on a string of recent pipeline catalysts, including FDA Breakthrough Therapy Designation for SMA candidate salanersen and positive Phase 3 data for lupus drug dapirolizumab pegol. The stock is up roughly 50% over the past year, but some analysts caution it looks overvalued given declining sales. The risk is integration and clinical execution on a still-early-stage asset.
Jun 17No significant overnight updatesNeutral▶
No material news in the last 48 hours.
Jun 16No significant overnight updatesNeutral▶
No material news in the last 48 hours.
Jun 15No significant overnight updatesNeutral▶
No material news in the last 48 hours.
Jun 14No significant overnight updatesNeutral▶
No material news in the last 48 hours.
May 21Biogen completed Apellis acquisition May 14 but diranersen Phase 2 missed primary endpoint causing 6.4% stock dropMixed▶
Biogen on May 14, 2026 completed its tender offer acquisition of Apellis Pharmaceuticals at $41 per share plus a CVR of up to $4. On the same day, the company released topline results from the Phase 2 CELIA study of diranersen (BIIB080) for early Alzheimer's, but the trial missed its primary dose-response endpoint causing shares to drop 6.4%. Despite the setback, Biogen plans to advance diranersen to registrational development based on broader signals showing reduction in tau pathology. Goldman Sachs raised its price target from $238 to $250 citing strong Leqembi sales. Several law firms initiated shareholder investigations following the trial results. Risk: clinical uncertainty for diranersen and ongoing legal scrutiny could pressure the stock near-term.
May 20Biogen closed $5.3B Apellis acquisition May 14 same day diranersen Phase 2 missed primary endpoint, sending shares down 6.4%.Mixed▶
Biogen on May 14, 2026 completed its approximately $5.3 billion acquisition of Apellis Pharmaceuticals, adding EMPAVELI and SYFOVRE products and contingent value rights tied to SYFOVRE sales — expected to lift long-term EPS growth. The same day, Biogen reported topline Phase 2 CELIA results for diranersen (BIIB080), the first study to show tau pathology reduction and cognitive benefit in early Alzheimer's; however, the trial missed its primary dose-response endpoint, triggering a 6.4% share drop and a shareholder investigation. Biogen plans to advance diranersen to registrational development citing robust biomarker and efficacy data. On May 8, Biogen updated on FDA Priority Review of LEQEMBI IQLIK subcutaneous starting dose. Goldman Sachs raised the PT to $250 from $238 (Buy) on Leqembi optimism; the stock had an 8-day winning streak with cumulative gains of 9.3% before the trial news, with market cap reaching roughly $30B.
May 19Biogen completes $41/share Apellis Pharmaceuticals acquisition while Phase 2 diranersen tau drug missed primary endpoint but advances to registrational study.Mixed▶
On May 14, 2026, Biogen announced completion of its tender offer to acquire Apellis Pharmaceuticals at $41 per share plus contingent value rights of up to $4 per share tied to SYFOVRE sales thresholds, with approximately 82.4% of Apellis shares tendered. The same day, Biogen released Phase 2 CELIA topline data for diranersen (BIIB080), an experimental tau-lowering Alzheimer's drug, which missed its primary dose-response endpoint, but management plans to advance the drug to registrational development based on broader signals. Shares fell 6.4% on the diranersen news despite the company's bullish framing. Goldman Sachs raised its price target to $250 from $238, citing strong Leqembi sales momentum. Several law firms initiated shareholder investigations following the trial outcome. Risk: regulatory and trial-execution uncertainty around diranersen could delay or block approval.
May 18Biogen completed $5.3B Apellis acquisition May 14 and posted Phase 2 CELIA diranersen data; Goldman raised PT to $250 from $238Positive▶
Biogen completed the acquisition of Apellis Pharmaceuticals on May 14 for $41/share cash plus contingent value rights of up to $4 tied to SYFOVRE sales milestones (~$5.3B deal). The same day, Biogen released Phase 2 CELIA topline results for diranersen (BIIB080), a tau-targeted Alzheimer's therapy — the trial missed its primary dose-response endpoint but showed reduction in tau pathology and cognitive benefit. Biogen will advance diranersen to registrational development. Stock reaction was mixed: pre-market surged +6.6% but lost ~6.4% intraday on the data miss; stock recently hit 52-week high of $202.64. Goldman raised PT to $250 from $238 (Buy); Guggenheim has $260 PT (Buy). Q1 2026 non-GAAP EPS of $3.57 beat $2.95 consensus with Leqembi sales up 74% YoY to $168M.
May 15Biogen completes $41 per share Apellis acquisition on May 14 and hits 52-week high at $202.64 on tau drug dataPositive▶
Biogen completed its acquisition of Apellis Pharmaceuticals on May 14, 2026, at $41 per share plus a contingent value right of up to $4 tied to SYFOVRE sales thresholds. About 105.69M shares (82.4% of outstanding) were validly tendered. Shares hit a 52-week high of $202.64, market cap $29.81B, up >13% YTD. Positive 18-month diranersen trial data showing strong tau reductions and slower cognitive decline drove a 7%+ premarket pop and 7-day winning streak. Q1 2026 results showed revenue of $2.48B (+2% YoY) and non-GAAP EPS of $3.57 (+18% YoY). Biogen also agreed to acquire TJ Biopharma's Greater China rights to felzartamab for up to $850M. The FDA extended review of Biogen/Eisai's Alzheimer's drug LEQEMBI subcutaneous starting dose by three months. Pipeline progress and M&A are driving bullish sentiment.
May 14FDA extends review of Biogen/Eisai's LEQEMBI IQLIK subcutaneous injection by 3 months to August 24, 2026 PDUFA date.Positive▶
On May 8, 2026, Eisai and Biogen announced the FDA extended its review of the supplemental BLA for once-weekly lecanemab-irmb subcutaneous injection (LEQEMBI IQLIK) as a starting dose for early Alzheimer's by three months to a new PDUFA action date of August 24, 2026. FDA has raised no approvability concerns. Despite the delay, Biogen stock hit a 52-week high of $202.64. Biogen also announced topline Phase 2 CELIA results for Diranersen (BIIB080), the first study to show tau pathology reduction and cognitive benefit in early Alzheimer's. Q1 2026 reported non-GAAP EPS of $3.57 (+18% YoY) and revenue of $2.48B (+2%), beating Street by 10%. Growth products including LEQEMBI and High Dose SPINRAZA were up 12%. Average analyst rating Buy with $208 target (11% upside).
May 13FDA extended review of Biogen's Leqembi Iqlik subcutaneous Alzheimer's injection by three months to Aug 24, 2026; Truist reiterated Hold.Mixed▶
The FDA extended its review of Biogen and Eisai's supplemental BLA for Leqembi Iqlik (lecanemab-irmb) subcutaneous autoinjector by three months, pushing the PDUFA date to August 24, 2026, from May 24. Truist Financial reiterated a Hold with a $203 target on May 10-11, characterizing the delay as a timing issue rather than a clinical setback. Biogen shares were trading around $199 on May 13, with 48 analysts at neutral consensus and a $190 median target. The company recently agreed to acquire Apellis Pharmaceuticals for $41/share ($5.6B). Updated FY EPS guidance is $14.25-$15.25. Risk is launch slope of the SC injector and continued reimbursement uncertainty.
May 12FDA extended review period for Biogen/Eisai's Leqembi Iqlik subcutaneous Alzheimer's autoinjector by three months to August 24, 2026.Mixed▶
The FDA extended the review period for Biogen's supplemental Biologics License Application for Leqembi Iqlik subcutaneous autoinjector by three months, pushing the new PDUFA action date to August 24, 2026. Biogen stock gained despite the delay as investors viewed the additional data submission as supportive. Recent analyst upgrades include Freedom Broker upgrading to Buy from Hold on May 1, with price targets raised to $190 at Truist, $200 at Citi, and $206 at Morgan Stanley. Q1 2026 revenue was $2.48 billion with 2% YoY revenue growth and 31% non-GAAP EPS growth. Management updated full-year EPS guidance to $14.25-$15.25 reflecting $1.00 of acquired IPR&D expense from the Greater China felzartamab deal.
Sector Peers
| Company | Price | Day | 1M | Fwd P/E | Beta | Mkt Cap |
|---|---|---|---|---|---|---|
| ABBVABBVIE | $216.79 | -2.01% | +2.0% | 13.3x | 0.31 | $382.5B |
| AMGNAMGEN | $337.43 | -1.24% | +1.8% | 14.4x | 0.42 | $182.2B |
| GILDGILEAD | $123.76 | -1.35% | -5.3% | 12.8x | 0.33 | $153.7B |
| VRTXVERTEX | $451.94 | -1.54% | +4.9% | 21.0x | 0.31 | $114.6B |
| REGNREGENERON | $609.97 | +0.34% | -6.1% | 11.3x | 0.24 | $63.9B |
| BIIBBIOGEN | $196.51 | -1.09% | +4.7% | 11.8x | 0.18 | $29.0B |
Key Fundamentals
RSI (14-Day)
52-Week Range
Moving Averages
Price above both MAs — bullish structure.